Abstract 512P
Background
Central nervous system germ cell tumors (CNS GCTs) are a group of rare heterogeneous CNS tumors. CNS GCTs are usually in midline location and mainly affect children and adolescents. The incidence of CNS GCTs is higher in Asia (11%) than that in Western Europe (4%) with a male predominance. The different tumor distribution demographically and high incidence in East Asia suggests a probable genetic background.
Methods
We collected samples including tissue and blood leukocyte control from 17 patients with CNS GCTs. All samples were tested using a 551-cancer related gene profiling, and somatic mutations, TMB, MSI and germline mutations were analyzed. The pathogenicity of germline mutations was categorized based on American College of Medical Genetics and Genomics guidelines. We screened out the pathogenic and likely pathogenic (P/LP) mutations of germline mutations and calculated the relative risk (RR) in our cohort compared to that in a control population (gnomAD). Then the relationship between mutation characteristics and clinical features were further analyzed, as well as the correlation with patient prognosis.
Results
In 17 patients with CNS GCTs, 4 patients (4/17) were found harboring germline pathogenic or likely-pathogenic mutations, respectively, in FANCA, FANCD2, FANCE, SDHA. All the four genes are Fanconi anemia (FA)-related genes. The RR of total FA mutations in patients with CNS GCTs was 21.589 (95% CI, 28.934-257.728; P value, 3.22E-07) compared to gnomAD controls. Then the 17 patients were divided into two groups, the FA group (with FA-related gene heterozygous germline P/LP mutations) and the non-FA group (without P/LP mutation). The results showed that pathological classification (P=0.00588) and site of lesion (P=0.00714) were significantly different in the two groups. There was no significant difference in gender, age and TMB between the two groups. The 4 recurrent patients were all in the non-FA group, but there was no statistical difference in prognosis between the two groups.
Conclusions
FA-related gene germline P/LP mutations increase the susceptibility to CNS GCTs. Moreover, the germline FA mutation may be related to the pathological subtype, site of lesion and prognosis, which needs to be verified with a large sample.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4P - Spatially resolved transcriptome elucidates bidirectional tertiary lymphoid structure interacts with tumor microenvironment of non-small cell lung cancer
Presenter: Xin Zhao
Session: Poster session 09
5P - Tertiary lymphoid structures (TLS) presence and stromal blood vessels heterogeneity differentially influence recurrence, lymphovascular, and perineural invasion in breast cancer molecular subtypes
Presenter: Andrei Cosma
Session: Poster session 09
6P - Combined single-cell and spatially resolved mapping of the human lymph node ecosystem reveals fundamental principles of lymphoma tissue organization
Presenter: Daniel Hübschmann
Session: Poster session 09
7P - Engineered salmonella blocks cancer metastasis by activating NK cells in an IFN-γ-dependent manner
Presenter: JIANDONG HUANG
Session: Poster session 09
8P - Modulating tumor microenvironment using a VEGF active immunotherapeutic approach in gastrointestinal tumors: Beyond angiogenesis modulation
Presenter: Mónica Bequet-Romero
Session: Poster session 09
9P - Identification of a μCT-based radiomic signature of CD8+ tumour infiltrating lymphocytes in an orthotopic murine model
Presenter: Giulia Mazzaschi
Session: Poster session 09
10P - Cancer cells induce intracellular gap formation in sinusoidal endothelial cells to produce liver metastasis through pro-inflammatory paracrine mechanisms
Presenter: Hoang Truong
Session: Poster session 09
11P - Targeting stromal cells to reverse immune suppression in triple-negative breast cancer
Presenter: Julia Chen
Session: Poster session 09
12P - Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Presenter: Christine Schuberth-Wagner
Session: Poster session 09
13P - Disrupting the immunosuppressive tumor microenvironment using genetically engineered macrophages for triple-negative breast cancer therapy
Presenter: Sabrina Traxel
Session: Poster session 09